SPOTLIGHT: Patent bill bogs down

A patent reform bill being argued in Congress has drawn a significant amount of protest from the biotech industry. But with a wide array of groups looking to influence the legislation, including the White House, the bill appears to have stalled in a Senate committee. High-tech companies, meanwhile, have been actively pushing for its passage. Report

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.